Trial Profile
A Study to Evaluate the Effect of Fingolimod on CSF Biomarkers Levels of Inflammation and Degeneration Following Switch from Other Disease Modifying Treatments in Patients with Relapsing Remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Biomarker; Pharmacodynamics
- 26 Feb 2016 New trial record